Do analysts rate CUE or PALI?

Palisade Bio has a consensus target price of $10.20, suggesting a potential upside of 401.23%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Palisade Bio 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Does the media prefer CUE or PALI?

In the previous week, Cue Biopharma and Cue Biopharma both had 1 articles in the media. Palisade Bio's average media sentiment score of 0.63 beat Cue Biopharma's score of 0.41 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palisade Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CUE or IRD?

Opus Genetics has a consensus price target of $10.67, suggesting a potential upside of 142.98%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Opus Genetics 2 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.81

Is CUE or IRD more profitable?

Cue Biopharma has a net margin of -59.65% compared to Opus Genetics' net margin of -892.36%. Cue Biopharma's return on equity of -98.30% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Cue Biopharma -59.65% -98.30% -53.69% Opus Genetics -892.36% -338.88% -191.21%

Does the media refer more to CUE or IRD?

In the previous week, Opus Genetics had 2 more articles in the media than Cue Biopharma. MarketBeat recorded 3 mentions for Opus Genetics and 1 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 0.41 beat Opus Genetics' score of 0.38 indicating that Cue Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Opus Genetics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CUE or SOPH?

SOPHiA GENETICS has a consensus price target of $7.50, indicating a potential upside of 53.37%. Given SOPHiA GENETICS's stronger consensus rating and higher probable upside, analysts clearly believe SOPHiA GENETICS is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SOPHiA GENETICS 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media refer more to CUE or SOPH?

In the previous week, SOPHiA GENETICS had 2 more articles in the media than Cue Biopharma. MarketBeat recorded 3 mentions for SOPHiA GENETICS and 1 mentions for Cue Biopharma. SOPHiA GENETICS's average media sentiment score of 0.91 beat Cue Biopharma's score of 0.41 indicating that SOPHiA GENETICS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SOPHiA GENETICS 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CUE or NMRA?

Neumora Therapeutics has a consensus price target of $7.67, indicating a potential upside of 334.37%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Neumora Therapeutics 2 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.56

Does the media refer more to CUE or NMRA?

In the previous week, Cue Biopharma and Cue Biopharma both had 1 articles in the media. Neumora Therapeutics' average media sentiment score of 0.93 beat Cue Biopharma's score of 0.41 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neumora Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate FENC or CUE?

Adherex Technologies currently has a consensus target price of $15.40, suggesting a potential upside of 64.65%. Given Adherex Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Adherex Technologies is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adherex Technologies 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Cue Biopharma (CUE) Competitors

$28.10 +1.19 (+4.42%)

As of 12:03 PM Eastern

Compare

CUE vs. PALI, IRD, SOPH, NMRA, and FENC

Should you buy Cue Biopharma stock or one of its competitors? MarketBeat compares Cue Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cue Biopharma include Palisade Bio (PALI), Opus Genetics (IRD), SOPHiA GENETICS (SOPH), Neumora Therapeutics (NMRA), and Adherex Technologies (FENC). These companies are all part of the "pharmaceutical products" industry.

How does Cue Biopharma compare to Palisade Bio?

Cue Biopharma (NASDAQ:CUE) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by company insiders. Comparatively, 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cue Biopharma has a beta of 2.52, suggesting that its share price is 152% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

In the previous week, Cue Biopharma and Cue Biopharma both had 1 articles in the media. Palisade Bio's average media sentiment score of 0.63 beat Cue Biopharma's score of 0.41 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palisade Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Palisade Bio's return on equity of -36.79% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Palisade Bio	N/A	-36.79%	-34.34%

Palisade Bio has lower revenue, but higher earnings than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	4.14	-$26.60M	-$5.58	N/A
Palisade Bio	$250K	1,412.94	-$16.78M	-$1.01	N/A

Palisade Bio has a consensus target price of $10.20, suggesting a potential upside of 401.23%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Palisade Bio beats Cue Biopharma on 12 of the 16 factors compared between the two stocks.

How does Cue Biopharma compare to Opus Genetics?

Cue Biopharma (NASDAQ:CUE) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Opus Genetics has a consensus price target of $10.67, suggesting a potential upside of 142.98%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.81

Cue Biopharma has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

In the previous week, Opus Genetics had 2 more articles in the media than Cue Biopharma. MarketBeat recorded 3 mentions for Opus Genetics and 1 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 0.41 beat Opus Genetics' score of 0.38 indicating that Cue Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Opus Genetics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cue Biopharma has higher revenue and earnings than Opus Genetics. Cue Biopharma is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	4.14	-$26.60M	-$5.58	N/A
Opus Genetics	$14.20M	25.17	-$49.59M	-$1.33	N/A

Cue Biopharma has a net margin of -59.65% compared to Opus Genetics' net margin of -892.36%. Cue Biopharma's return on equity of -98.30% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Opus Genetics	-892.36%	-338.88%	-191.21%

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by company insiders. Comparatively, 11.7% of Opus Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Cue Biopharma beats Opus Genetics on 9 of the 17 factors compared between the two stocks.

How does Cue Biopharma compare to SOPHiA GENETICS?

Cue Biopharma (NASDAQ:CUE) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

SOPHiA GENETICS has a net margin of -44.48% compared to Cue Biopharma's net margin of -59.65%. SOPHiA GENETICS's return on equity of -62.74% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%

Cue Biopharma has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, SOPHiA GENETICS had 2 more articles in the media than Cue Biopharma. MarketBeat recorded 3 mentions for SOPHiA GENETICS and 1 mentions for Cue Biopharma. SOPHiA GENETICS's average media sentiment score of 0.91 beat Cue Biopharma's score of 0.41 indicating that SOPHiA GENETICS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SOPHiA GENETICS	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SOPHiA GENETICS has a consensus price target of $7.50, indicating a potential upside of 53.37%. Given SOPHiA GENETICS's stronger consensus rating and higher probable upside, analysts clearly believe SOPHiA GENETICS is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cue Biopharma has higher earnings, but lower revenue than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	4.14	-$26.60M	-$5.58	N/A
SOPHiA GENETICS	$77.27M	4.33	-$79M	-$0.52	N/A

Summary

SOPHiA GENETICS beats Cue Biopharma on 11 of the 16 factors compared between the two stocks.

How does Cue Biopharma compare to Neumora Therapeutics?

Cue Biopharma (NASDAQ:CUE) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Neumora Therapeutics has a consensus price target of $7.67, indicating a potential upside of 334.37%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.56

Cue Biopharma has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.73, meaning that its stock price is 173% more volatile than the broader market.

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by company insiders. Comparatively, 26.9% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Cue Biopharma and Cue Biopharma both had 1 articles in the media. Neumora Therapeutics' average media sentiment score of 0.93 beat Cue Biopharma's score of 0.41 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neumora Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cue Biopharma has higher revenue and earnings than Neumora Therapeutics. Cue Biopharma is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	4.14	-$26.60M	-$5.58	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A

Neumora Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Cue Biopharma's return on equity of -98.30% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Neumora Therapeutics	N/A	-181.70%	-119.15%

Summary

Neumora Therapeutics beats Cue Biopharma on 11 of the 15 factors compared between the two stocks.

How does Cue Biopharma compare to Adherex Technologies?

Adherex Technologies (NASDAQ:FENC) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Adherex Technologies currently has a consensus target price of $15.40, suggesting a potential upside of 64.65%. Given Adherex Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Adherex Technologies is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Cue Biopharma had 1 more articles in the media than Adherex Technologies. MarketBeat recorded 1 mentions for Cue Biopharma and 0 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 1.62 beat Cue Biopharma's score of 0.41 indicating that Adherex Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Adherex Technologies	Very Positive
Cue Biopharma	Neutral

55.5% of Adherex Technologies shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 10.7% of Adherex Technologies shares are owned by company insiders. Comparatively, 14.6% of Cue Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Adherex Technologies has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.52, meaning that its share price is 152% more volatile than the broader market.

Adherex Technologies has a net margin of -17.12% compared to Cue Biopharma's net margin of -59.65%. Adherex Technologies' return on equity of -43.87% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-17.12%	-43.87%	-11.35%
Cue Biopharma	-59.65%	-98.30%	-53.69%

Adherex Technologies has higher revenue and earnings than Cue Biopharma. Adherex Technologies is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$44.64M	7.27	-$9.74M	-$0.29	N/A
Cue Biopharma	$27.47M	4.14	-$26.60M	-$5.58	N/A

Summary

Adherex Technologies beats Cue Biopharma on 13 of the 17 factors compared between the two stocks.

Get Cue Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CUE vs. The Competition

Export

Metric	Cue Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$113.80M	$3.35B	$6.45B	$12.42B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-5.03	18.82	23.89	24.35
Price / Sales	4.14	322.47	524.38	119.30
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	2.79	6.85	10.06	6.74
Net Income	-$26.60M	$24.15M	$3.56B	$337.03M
7 Day Performance	24.12%	-1.87%	-0.60%	0.24%
1 Month Performance	N/A	N/A	N/A	-1.60%
1 Year Performance	-94.96%	49.61%	29.29%	34.04%

Cue Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CUE Cue Biopharma	0.5328 of 5 stars	$28.10 +4.4%	N/A	-95.3%	$113.80M	$27.47M	N/A	60
PALI Palisade Bio	1.7042 of 5 stars	$1.99 +2.1%	$10.20 +412.6%	+162.2%	$345.42M	$250K	N/A	10
IRD Opus Genetics	3.2671 of 5 stars	$4.24 -0.5%	$10.18 +140.1%	+315.8%	$345.14M	$14.20M	N/A	14	Analyst Forecast
SOPH SOPHiA GENETICS	2.3944 of 5 stars	$5.00 +2.5%	$7.50 +50.0%	+57.8%	$342.45M	$77.27M	N/A	520
NMRA Neumora Therapeutics	3.0718 of 5 stars	$1.84 -0.8%	$7.67 +317.8%	+134.2%	$339.99M	N/A	N/A	108	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CUE) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cue Biopharma (CUE) Competitors

CUE vs. PALI, IRD, SOPH, NMRA, and FENC

How does Cue Biopharma compare to Palisade Bio?

Summary

How does Cue Biopharma compare to Opus Genetics?

Summary

How does Cue Biopharma compare to SOPHiA GENETICS?

Summary

How does Cue Biopharma compare to Neumora Therapeutics?

Summary

How does Cue Biopharma compare to Adherex Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE vs. The Competition

Cue Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cue Biopharma (CUE) Competitors

CUE vs. PALI, IRD, SOPH, NMRA, and FENC

How does Cue Biopharma compare to Palisade Bio?

Do insiders & institutionals hold more shares of CUE or PALI?

Which has more volatility and risk, CUE or PALI?

Does the media prefer CUE or PALI?

Is CUE or PALI more profitable?

Which has stronger earnings & valuation, CUE or PALI?

Do analysts rate CUE or PALI?

Summary

How does Cue Biopharma compare to Opus Genetics?

Do analysts rate CUE or IRD?

Which has more volatility and risk, CUE or IRD?

Does the media refer more to CUE or IRD?

Which has better earnings & valuation, CUE or IRD?

Is CUE or IRD more profitable?

Do insiders & institutionals believe in CUE or IRD?

Summary

How does Cue Biopharma compare to SOPHiA GENETICS?

Is CUE or SOPH more profitable?

Which has more risk and volatility, CUE or SOPH?

Do insiders and institutionals have more ownership in CUE or SOPH?

Does the media refer more to CUE or SOPH?

Do analysts prefer CUE or SOPH?

Which has stronger earnings & valuation, CUE or SOPH?

Summary

How does Cue Biopharma compare to Neumora Therapeutics?

Do analysts recommend CUE or NMRA?

Which has more volatility and risk, CUE or NMRA?

Do institutionals and insiders have more ownership in CUE or NMRA?

Does the media refer more to CUE or NMRA?

Which has better earnings & valuation, CUE or NMRA?

Is CUE or NMRA more profitable?

Summary

How does Cue Biopharma compare to Adherex Technologies?

Do analysts rate FENC or CUE?

Does the media prefer FENC or CUE?

Do institutionals and insiders have more ownership in FENC or CUE?

Which has more volatility & risk, FENC or CUE?

Is FENC or CUE more profitable?

Which has better earnings and valuation, FENC or CUE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE vs. The Competition

Cue Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools